Cargando…
Donepezil for mild cognitive impairment in Parkinson’s disease
We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks...
Autores principales: | Baik, Kyoungwon, Kim, Seon Myeong, Jung, Jin Ho, Lee, Yang Hyun, Chung, Seok Jong, Yoo, Han Soo, Ye, Byoung Seok, Lee, Phil Hyu, Sohn, Young H., Kang, Seung Wan, Kang, Suk Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910590/ https://www.ncbi.nlm.nih.gov/pubmed/33637811 http://dx.doi.org/10.1038/s41598-021-84243-4 |
Ejemplares similares
-
White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
por: Chung, Seok Jong, et al.
Publicado: (2020) -
Implication of EEG theta/alpha and theta/beta ratio in Alzheimer’s and Lewy body disease
por: Baik, Kyoungwon, et al.
Publicado: (2022) -
Comparison Between (18)F-Florapronol and (18)F-Florbetaben Imaging in Patients With Cognitive Impairment
por: Baik, Kyoungwon, et al.
Publicado: (2023) -
The Influence of Body Mass Index at Diagnosis on Cognitive Decline in Parkinson's Disease
por: Yoo, Han Soo, et al.
Publicado: (2019) -
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease
por: Lee, Young-gun, et al.
Publicado: (2022)